Abstract

PROCEPT BioRobotics will release its quarterly results on February 24, 2026 Post Market, with investors watching top-line momentum, margins, and EPS trends amid accelerating urology adoption and scaling in consumables and systems.

Market Forecast

Consensus and company-indicated projections for the current quarter point to revenue of $94.14 million, up 40.97% year over year, with an estimated EBIT of -$19.60 million and estimated EPS of -$0.324. Forecast gross margin and net margin are not explicitly disclosed; based on the prior quarter trend, investors expect healthy gross margin support from mix and scale, while net margin likely remains negative with ongoing growth investments. The main business is expected to be driven by consumables and system placements, with services contributing recurring revenue and utilization stability. The most promising segment appears to be “手件和其他消耗品” (handpieces and other consumables), which scales with installed base utilization; recent quarter revenue was $49.73 million and will likely lead growth given procedure volume expansion.

Last Quarter Review

PROCEPT BioRobotics reported last quarter gross profit margin of 64.81% and net profit margin of -25.70%. Net profit attributable to the parent company was -$21.41 million, reflecting a quarter-on-quarter change of -9.36% (interpreted as a deterioration on a sequential basis). By segment, revenue totaled $83.33 million: “手件和其他消耗品” at $49.73 million, “系统销售和租赁” (system sales and leasing) at $28.14 million, and “服务” (services) at $5.46 million. A key highlight was stronger-than-expected top-line execution, with actual revenue of $83.33 million exceeding the prior forecast by $2.38 million, while adjusted EPS delivered -$0.38 versus an expected -$0.412, indicating modest operating leverage despite continued investment. In the main business, consumables demonstrated robust recurring revenue characteristics tied to procedure volumes, while system placements broadened the installed base and supported future consumable pull-through.

Current Quarter Outlook

Main Business: Consumables and System Placements

The company’s main business is anchored around consumables utilization and system sales/leasing across urology centers. Consumables scale directly with procedure volume, and the prior quarter’s $49.73 million in “手件和其他消耗品” confirms strong utilization across the installed base. System placements at $28.14 million support future recurring consumable revenue as centers ramp procedures after installation, and services at $5.46 million provide recurring stability and maintenance revenue. For the quarter to be reported, the interplay between new placements and utilization rates is central. High-single to low-double-digit sequential growth in consumables would be consistent with ramping centers and growing physician adoption, while system sales can show lumpiness depending on capital budgeting cycles and purchasing approvals. Margin dynamics hinge on production efficiency and mix; consumables generally carry higher gross margin than capital systems, suggesting that favorable mix can sustain gross margin near the mid-60% area, even as the company invests in salesforce expansion and clinical education.

Most Promising Segment: Handpieces and Other Consumables

Handpieces and other consumables tend to be the largest growth lever because they monetize every procedure, scale with the installed base, and typically carry robust gross margins. With $49.73 million recorded last quarter, this segment appears well-positioned to lead growth again as centers increase throughput and scheduling utilization improves. Year-over-year growth potential is supported by an expanding base of trained physicians, maturing accounts that move from trial to routine usage, and increased patient referrals as patient awareness rises. In the current quarter, sustained pull-through is likely to anchor total revenue near the $94.14 million estimate. Key variables include procedure volume growth, case mix complexity, and any seasonal scheduling patterns. If case volumes continue to expand at a pace consistent with installed-base growth, the consumables segment should be the primary driver of revenue upside versus estimates, reinforcing margin support due to its favorable gross profit profile.

Stock Price Drivers This Quarter

Stock performance will be influenced by the degree to which revenue outperforms the $94.14 million estimate and whether operating losses narrow relative to the -$19.60 million EBIT projection. Investors will watch for commentary on gross margin trajectory, including any manufacturing efficiencies or pricing strategies that could stabilize margins in the mid-60% range. Updates on capital systems demand—particularly the cadence of new installations, leasing mix, and geographic expansion—will shape expectations for second-half consumable pull-through and overall growth durability. Management’s guidance and qualitative commentary on utilization ramp, backlog, and pipeline will be equally important. Signals of accelerating procedure growth, stronger conversion of new centers to routine utilization, and consistent reimbursement environments across regions can underpin constructive views on the sustainability of top-line growth. Any signs of cost discipline or improved operating leverage, even as the company invests in market expansion, could help reframe the path toward breakeven and eventual profitability.

Analyst Opinions

Analyst commentary in recent months has tilted constructive, with a majority highlighting durable top-line momentum supported by consumables and growing installations, balanced against ongoing operating losses associated with scaling. Several institutions point to upside potential if procedure volumes continue to ramp and system placements remain steady, noting prior-quarter revenue performance exceeded forecasts and EPS beat modestly. Bullish views emphasize the recurring nature of consumables and the runway from center activation, suggesting that near-term results could track at or slightly above current revenue estimates while margins remain supported by mix. Among well-followed analysts, views that favor sustained adoption and utilization gains underpin a constructive near-term outlook. These perspectives focus on the evidence of consistent demand, dependable revenue recurrence from consumables, and improving operational execution demonstrated by last quarter’s revenue and EPS outperformance relative to estimates. The consensus majority expects revenue growth around 40–41% year over year with potential for small upside if utilization trends remain intact, while maintaining caution that EBIT and EPS could stay negative as the company invests in its growth strategy.